What is the first-line treatment for Clostridioides (C.) difficile infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

First-Line Treatment for Clostridioides difficile Infection

Vancomycin 125 mg orally four times daily for 10 days is the preferred first-line treatment for both non-severe and severe C. difficile infection, with fidaxomicin 200 mg orally twice daily for 10 days as an equally acceptable alternative that offers lower recurrence rates. 1

Treatment Algorithm by Disease Severity

Non-Severe CDI

  • Vancomycin 125 mg orally four times daily for 10 days is the current standard of care 1
  • Fidaxomicin 200 mg orally twice daily for 10 days is an equally acceptable first-line option with superior recurrence prevention (13.3% vs 24.0% with vancomycin) 1
  • Metronidazole is no longer recommended as first-line therapy for initial CDI due to vancomycin's superior clinical cure rates and metronidazole's cumulative neurotoxicity risk 1, 2, 3, 4

Severe CDI

  • Vancomycin 125 mg orally four times daily for 10 days is the definitive treatment 1, 2
  • Patients treated with vancomycin have lower all-cause 30-day mortality compared to metronidazole 2
  • Metronidazole should not be used for severe CDI under any circumstances 1

Severe CDI is defined by: temperature >38.5°C, white blood cell count >15,000 cells/mL, serum creatinine >1.5 mg/dL, albumin <2.5 mg/dL, or 10 or more bowel movements within 24 hours 1, 2

When to Choose Fidaxomicin Over Vancomycin

Fidaxomicin should be strongly considered for patients at high risk of recurrence, including:

  • Age >65 years 1
  • Ongoing antibiotic use for other infections 1
  • Proton pump inhibitor use 1
  • Concern for vancomycin-resistant Enterococci (VRE) acquisition, as fidaxomicin causes VRE in only 7% vs 31% with vancomycin 1

Critical Management Steps

  • Immediately discontinue the inciting antibiotic if clinically feasible, as this significantly influences recurrence risk 1
  • Never use IV vancomycin for CDI treatment – it is not excreted into the colon and is completely ineffective 1
  • Do not perform a "test of cure" after completing CDI treatment 1, 2

When Oral Therapy Is Not Possible

For patients unable to take oral medications with severe CDI:

  • Metronidazole 500 mg IV three times daily PLUS 1
  • Vancomycin 500 mg via nasogastric tube four times daily AND/OR 1
  • Vancomycin 500 mg retention enema in 100 mL normal saline every 4-12 hours 1

Common Pitfalls to Avoid

  • Do not use metronidazole for initial CDI treatment – older 2009 guidelines recommended this for non-severe disease 5, but current evidence demonstrates vancomycin's superiority and metronidazole's neurotoxicity risk with prolonged use 1, 2
  • Do not confuse disease severity – the same vancomycin dose (125 mg four times daily) is used for both non-severe and severe CDI; higher doses provide no additional benefit 1
  • Do not delay treatment while awaiting test results if clinical suspicion is high, as severe CDI can progress rapidly to fulminant disease with hypotension, shock, ileus, or toxic megacolon 2, 4

References

Guideline

First-Line Treatment for Clostridioides difficile Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

First-Line Treatment for Clostridioides difficile Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Therapeutics for Clostridioides difficile infection: molecules and microbes.

Expert review of gastroenterology & hepatology, 2023

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.